Inotiv, Inc. Common Stock (NOTV)
Inotiv, Inc. (NOTV) is a contract research organization (CRO) that provides research and development services primarily to biopharmaceutical and biotechnology companies. The company specializes in preclinical research, including pharmacology, toxicology, and ADME (absorption, distribution, metabolism, and excretion) testing, supporting drug discovery and development processes. Inotiv operates laboratories across the United States and offers tailored solutions to accelerate the development of new therapies.
Company News
Inotiv reported Q3 fiscal 2025 revenue of $130.7 million, a 23.5% increase from the previous year, driven by growth in Research Models and Services. The company reduced its operating loss and received a positive update from the SEC regarding a previous investigation.
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: RL) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintaine...
Discover rare investment picks for December 2023 that you might have overlooked from analysts who make less-frequent recommendations. Read more here.